A phase II study of S-1, oxaliplatin, oral leucovorin, and bevacizumab combination therapy (SOLA) in patients with unresectable metastatic colorectal cancer
Crossref DOI link: https://doi.org/10.1007/s00280-015-2825-5
Published Online: 2015-07-22
Published Print: 2015-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Nishina, Tomohiro
Kato, Takeshi
Yamazaki, Kentaro
Yoshino, Takayuki
Miyata, Yoshinori
Esaki, Taito
Moriwaki, Toshikazu
Boku, Narikazu
Hyodo, Ichinosuke
Funding for this research was provided by:
Taiho Pharmaceutical Co., Ltd., Tokyo, Japan
Text and Data Mining valid from 2015-07-22